Covers development and preclinical testing of bispecific chimeric autoantibody receptor T cells targeting two acetylcholine receptor subunits in myasthenia gravis models.
Key Takeaways
- IgLON5-Fc served as a negative control antigen
- Dots show the results of each technical replicate
- C Expression of AChRa1 CAAR and AChRb1 CAAR in primary human T cells was validated by flow cytometry